Advances in Monoclonal Antibody Therapeutics Targeting Insulin Resistance in Cancer
Monoclonal antibodies targeting IGF-1R, IL-6, IL-1β, TNF-α, PD-1, PD-L1, and CTLA-4 may counteract insulin resistance in cancer.
Therapeutic Area
Therapeutic area intelligence for Monoclonal Antibodies with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
NMR spectroscopy identifies arginine and lysine as effective excipients that reduce mAb viscosity, while proline and glycine promote clustering.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.